Alliance
C4U and Sumitomo Pharma enter into License Agreement
C4U and Sumitomo Pharma have entered into a license agreement, granting Sumitomo Pharma the right to develop and market regenerative medicine product for central nervous system diseases utilizing CRISPR-Cas3 technology.
C4U and Sumitomo Pharma have conducted three collaborative research projects since 2021, one of which resulted in the conclusion of this agreement.